Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]

• Linglong Deng,
• Hannah Petrek,
• Mei-Juan Tu,
• Neelu Batra,
• Ai-Xi Yu,
• Ai-Ming Yu

Affiliations

Linglong Deng

Department of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430072, China; Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

Hannah Petrek

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

Mei-Juan Tu

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

Neelu Batra

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

Ai-Xi Yu

Department of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430072, China; Corresponding authors.

Ai-Ming Yu

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA; Corresponding authors.